Roche's Genentech Vabysmo New Long-Term Data Shows Sustained Retinal Drying And Vision Improvements In Retinal Vein Occlusion (RVO)
Roche's Genentech Vabysmo New Long-Term Data Shows Sustained Retinal Drying And Vision Improvements In Retinal Vein Occlusion (RVO)
罗氏基因泰克Vabysmo新的长期数据显示，视网膜持续干燥，视网膜静脉闭塞（RVO）视力得到改善
– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –
Vabysmo能够持续有效地干燥视网膜液体，通常伴有变形或模糊视觉。
– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –
接受Vabysmo治疗的人中，高达60％的人能够将治疗间隔延长至三到四个月。
– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024 –
两项全球Phase III RVO研究的详细结果将在2024年的“血管生成、渗出和退化”会议上介绍。
– Vabysmo is approved in the U.S. for RVO, and in more than 90 countries around the world for people living with wet AMD and DME –
Vabysmo已在美国获得RVO的批准，并在全球90多个国家为患有湿性黄斑变性和DME的人提供服务。